Robert Hsu

Assistant Professor of Clinical Medicine

Director of LAC Lung Medical Oncology

Image of Robert Hsu
Is this your profile? Click to edit

Overview

Dr. Robert Hsu is an Assistant Professor of Medicine in the Division of Medical Oncology at University of Southern California focusing on thoracic cancers. Dr. Hsu completed his medical school training at Tulane University School of Medicine followed by Internal Medicine residency training at University of Miami/Jackson Memorial and then hematology and oncology training at Los Angeles County+University of Southern California where he served as chief fellow for medical oncology.

His research interests are focused in lung cancer research along with cancer disparities across multiple solid tumor types. His research includes projects involving comprehensive genomic profiling looking at biomarkers in lung cancer, retrospective database work looking at lung cancer patients treated at USC looking at mutation differences among different ethnicities particularly Hispanics, epidemiological research looking at lung and thyroid cancer incorporating the California Cancer Registry, and translational research looking at tumor microenvironment and ethnicities in lung and breast cancer.

Awards

  • National Institutes of Health: NIH Summer Student Intramural Award, 2007
  • Cornell University: Cornell University Community Partnership Grant, 2008
  • Cornell University: Cum Laude Distinction, 2009
  • AmeriCorps: AmeriCorps Segal Education Award, 2010
     – 2011
  • Tulane University School of Medicine: Southern Section-American Federation for Clinical Research Travel Award, 2014
  • Asian Pacific American Medical Student President’s Award for Distinguished Service, 2017
  • Summit on National and Global Cancer Health Disparities Travel Award, 2018
  • University of Southern California: Best Research Award at USC Medical Oncology Fellows Research Symposium, 2021
     – 2022
  • International Association for the Study of Lung Cancer: Academy Award, 2024

Education and Training

  • Cornell University, Ithaca, NY — BS — 2009 — Biological Sciences & Biometry & Statistics
  • University of Toledo, Toledo, OH — MS — 2012 — Biomedical Sciences
  • Tulane University School of Medicine, New Orleans, LA — MD — 2016
  • University of Miami/Jackson Memorial Hospital, Miami, FL — 2019 — Residency, Internal Medicine
  • University of Southern California, Los Angeles, CA — 2022 — Fellowship, Hematology & Oncology

Research Funding

  • A phase II study of subcutaneous atezolizumab in NSCLC patients using a decentralized clinical trial model
    Robert A. Winn Excellence in Clinical Trials Career Development Award · Oct 1, 2024 – Jan 1, 2027

Research Keywords

  • Cancer Disparities
  • Cancer Tumor Microenvironment/Immunotherapy
  • Lung Cancer
  • Hispanic and Asian Pacific Islander Health

Publications

  • Development of a 3D-3 co-culture microbead consisting of cancer-associated fibroblasts and human umbilical vein endothelial cells for the anti-tumor drug assessment of lung cancer. Transl Lung Cancer Res. 2025 Jun 30; 14(6):2159-2179.. View in PubMed
  • Impact of Modern Systemic Therapies on Survival in Patients with Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Review. Drugs Real World Outcomes. 2025 Jun; 12(2):295-300.. View in PubMed
  • Advances in adoptive cell therapies in small cell lung cancer. Explor Target Antitumor Ther. 2025; 6:1002302.. View in PubMed
  • Gender and Geographic Characteristics Among Thoracic, GI, and Breast Oncology Editorial Boards: Disparities and Measures to Address Gaps. JCO Glob Oncol. 2025 Feb; 11:e2400656.. View in PubMed
  • Deciding where Trop-2 directed antibody drug conjugates work in non-small cell lung cancer: the not so straightforward road. Transl Cancer Res. 2025 Feb 28; 14(2):679-684.. View in PubMed
  • Real-World Incidence of Anaplastic Lymphoma Kinase Alterations in Hispanics with Non-Small Cell Lung Cancer at a Large Academic Institution in Los Angeles. Cancer Res Commun. 2025 02 01; 5(2):277-286.. View in PubMed
  • Treatment approaches in advanced penile cancer: targeted therapies and immunotherapy. Front Oncol. 2024; 14:1457006.. View in PubMed
  • The current landscape and prospects of antibody-drug conjugates for lung cancer brain metastases: a narrative review. Transl Lung Cancer Res. 2024 Dec 31; 13(12):3778-3794.. View in PubMed
  • Assessing the predictive role of platelet-lymphocyte ratio in EGFR-mutated non-small cell lung cancer patients treated with tyrosine kinase inhibitors: an analysis across TKI generations. Discov Oncol. 2024 Nov 21; 15(1):689.. View in PubMed
  • Addressing the unmet need in NSCLC progression with advances in second-line therapeutics. Explor Target Antitumor Ther. 2024; 5(6):1297-1320.. View in PubMed